306 related articles for article (PubMed ID: 36036316)
1. The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes.
Kuang Z; Hou N; Kan C; Han F; Qiu H; Sun X
Int Urol Nephrol; 2023 Mar; 55(3):617-629. PubMed ID: 36036316
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
Zou H; Zhou B; Xu G
Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
[TBL] [Abstract][Full Text] [Related]
4. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.
Gómez-Huelgas R; Sanz-Cánovas J; Cobos-Palacios L; López-Sampalo A; Pérez-Belmonte LM
Eur J Intern Med; 2022 Feb; 96():26-33. PubMed ID: 34799233
[TBL] [Abstract][Full Text] [Related]
6. Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System.
Puglisi S; Rossini A; Poli R; Dughera F; Pia A; Terzolo M; Reimondo G
Front Endocrinol (Lausanne); 2021; 12():738848. PubMed ID: 34745006
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 Receptor Agonists and Kidney Protection.
Greco EV; Russo G; Giandalia A; Viazzi F; Pontremoli R; De Cosmo S
Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159279
[TBL] [Abstract][Full Text] [Related]
8. Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists.
Prattichizzo F; de Candia P; Ceriello A
Metabolism; 2021 Jul; 120():154799. PubMed ID: 34029597
[TBL] [Abstract][Full Text] [Related]
9. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.
Sarafidis P; Ferro CJ; Morales E; Ortiz A; Malyszko J; Hojs R; Khazim K; Ekart R; Valdivielso J; Fouque D; London GM; Massy Z; Ruggenenti P; Porrini E; Wiecek A; Zoccali C; Mallamaci F; Hornum M
Nephrol Dial Transplant; 2019 Feb; 34(2):208-230. PubMed ID: 30753708
[TBL] [Abstract][Full Text] [Related]
10. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.
Yang S; He W; Zhao L; Mi Y
PLoS One; 2022; 17(4):e0267025. PubMed ID: 35421174
[TBL] [Abstract][Full Text] [Related]
11. New Glucose-Lowering Agents for Diabetic Kidney Disease.
de Vos LC; Hettige TS; Cooper ME
Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Management of Diabetic Nephropathy.
Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
[TBL] [Abstract][Full Text] [Related]
13. Impact of CVOTs in primary and secondary prevention of kidney disease.
De Cosmo S; Viazzi F; Piscitelli P; Leoncini G; Mirijello A; Bonino B; Pontremoli R
Diabetes Res Clin Pract; 2019 Nov; 157():107907. PubMed ID: 31676332
[TBL] [Abstract][Full Text] [Related]
14. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
15. Advancements in diabetic kidney disease management: integrating innovative therapies and targeted drug development.
Ghose S; Satariano M; Korada S; Cahill T; Shah R; Raina R
Am J Physiol Endocrinol Metab; 2024 Jun; 326(6):E791-E806. PubMed ID: 38630049
[TBL] [Abstract][Full Text] [Related]
16. Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.
Foer D; Beeler PE; Cui J; Karlson EW; Bates DW; Cahill KN
Am J Respir Crit Care Med; 2021 Apr; 203(7):831-840. PubMed ID: 33052715
[No Abstract] [Full Text] [Related]
17. Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients.
Kim MK; Kim DM
J Diabetes Investig; 2021 Jun; 12(6):914-916. PubMed ID: 33759351
[TBL] [Abstract][Full Text] [Related]
18. [The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease].
Wang YJ; Hao CM
Sheng Li Xue Bao; 2018 Dec; 70(6):663-669. PubMed ID: 30560277
[TBL] [Abstract][Full Text] [Related]
19. Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point?
Lee B; Holstein-Rathlou NH; Sosnovtseva O; Sørensen CM
Am J Physiol Cell Physiol; 2023 Jul; 325(1):C243-C256. PubMed ID: 37273240
[TBL] [Abstract][Full Text] [Related]
20. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.
Bailey CJ
Lancet Diabetes Endocrinol; 2020 Feb; 8(2):97-99. PubMed ID: 31843565
[No Abstract] [Full Text] [Related]
[Next] [New Search]